Researcher receives grant to help halt HIV replication

August 20, 2001

ST. LOUIS-Duane Grandgenett, Ph.D., professor of molecular virology at the Institute of Molecular Virology (IMV) at Saint Louis University School of Medicine, has received two grants totaling nearly a million dollars to study ways of inhibiting HIV replication in humans. The grants are from the National Institute of Allergy and Infectious Diseases ($866,250) and the American Foundation for AIDS Research ($75,000).

"Busch Stadium holds about 47,000 people," Dr. Grandgenett said. "Every three days, that's approximately how many people in the world become infected with HIV. It's a huge problem to say the least and the fundamental work we're doing in the lab is vital to understanding HIV's method of operation."

The monetary awards support Dr. Grandgenett's exploration of integrase, a protein he and his colleagues at Saint Louis University discovered in 1978. Integrase is one of three HIV proteins crucial to the infection's survival. The first protein, reverse transcriptase, converts the ribonucleic acid (RNA) in HIV into deoxyribonucleic acid (DNA). Integrase then inserts the HIV DNA into the immune cell's DNA, making it a permanent part of the cell. The third protein, protease, helps the newly infected cell reproduce the virus. Millions of HIV tainted cells can be launched from a single infected cell.

Drugs such as AZT and drug combinations (cocktails) exist to inhibit reverse transcriptase and protease but, as of yet, there are no drugs to counter integrase.

"Drugs that target integrase would be a valuable accompaniment to the current inhibitors of HIV," Dr. Grandgenett said. "The current drug combinations available have side effects that are very difficult to tolerate. Finding a way to inhibit integrase could not only help us attack the virus on all three fronts but also could lessen the side effects of current therapy."

Dr. Grandgenett pointed out that studying the basic mechanisms of HIV is critical to finding effective treatment for infected individuals and for developing vaccines.
-end-
Established in 1836, Saint Louis University School of Medicine has the distinction of awarding the first M.D. degree west of the Mississippi River. Saint Louis University School of Medicine is a pioneer in geriatric medicine, organ transplantation, chronic disease prevention, cardiovascular disease, neurosciences and vaccine research, among others. The SLU School of Medicine trains physicians and biomedical scientists, conducts medical research, and provides health services on a local, national and international level.

Saint Louis University

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.